Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - dulaglutide -

United States - English - NLM (National Library of Medicine)

eli lilly and company - dulaglutide (unii: wtt295hsy5) (dulaglutide - unii:wtt295hsy5) - dulaglutide 0.75 mg in 0.5 ml - trulicity® is indicated: - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. - to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. limitations of use trulicity: - has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - should not be used in patients with type 1 diabetes mellitus. - has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see warnings and precautions (5.6)] . trulicity is contraindicated in patients with: - personal or family history of medullary thyroid carcino

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - dulaglutide, quantity: 1.5 mg - injection, solution - excipient ingredients: citric acid; water for injections; mannitol; polysorbate 80; sodium citrate dihydrate - type 2 diabetes mellitus: glycaemic control - trulicity is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: ? as monotherapy. ? in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations).,type 2 diabetes mellitus: reduction in risk of major adverse cardiovascular events - trulicity is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have: ? established cardiovascular disease or ? multiple cardiovascular risk factors

Israel - English - Ministry of Health

eli lilly israel ltd, israel - dulaglutide - solution for injection - dulaglutide 0.75 mg / 0.5 ml - dulaglutide - type 2 diabetes mellitustrulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - dulaglutide - solution for injection - dulaglutide 1.5 mg / 0.5 ml - dulaglutide - type 2 diabetes mellitustrulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

eli lilly and company - dulaglutide - solution for injection - 0,75mg/0.5ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

eli lilly and company - dulaglutide - solution for injection - 1,5mg/0.5ml

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 0.75mg - dulaglutide 0.75mg - incretin mimetics

Canada - English - Health Canada

eli lilly canada inc - dulaglutide - solution - 1.5mg - dulaglutide 1.5mg - incretin mimetics